A Human Acellular Vessel, or HAV, is a new type of graft that is being investigated in research studies for adults with kidney disease on hemodialysis.
How does the HAV work?
Who may qualify?
The potential benefits of the HAV over an arteriovenous fistula are that it may involve a lower risk of infection and enable hemodialysis to be performed earlier.
If you have questions or would like to see if your patient qualifies for this clinical study, contact:
Maria Myslinski, RN or Matthew Bizak, RN
For more information, please visit the sites below.
For all trials being performed by The Vascular Experts at one of our locations, please contact us via phone or website if you have any questions or would like additional information.